Citizens JMP lowered the firm’s price target on Quince Therapeutics (QNCX) to $8 from $9 and keeps an Outperform rating on the shares. The firm is impressed with management’s execution in completing enrollment for the pivotal NEAT trial, which is set up for success, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics Reports Q2 2025 Financial Results
- Quince Therapeutics reports Q2 EPS (34c), consensus (23c)
- QNCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Quince Therapeutics initiated with an Outperform at Citizens JMP
- Quince Therapeutics files to sell 6.67M shares of common stock for holders